ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

ClinicalTrials.gov ID: NCT06615479

Public ClinicalTrials.gov record NCT06615479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

Study identification

NCT ID
NCT06615479
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Enrollment
440 participants

Conditions and interventions

Interventions

  • BMS-986393 Drug
  • Carfilzomib Drug
  • Cyclophosphamide Drug
  • Daratumumab Drug
  • Dexamethasone Drug
  • Fludarabine Drug
  • Pomalidomide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 11, 2025
Primary completion
Dec 29, 2027
Completion
Jun 21, 2032
Last update posted
Apr 13, 2026

2025 – 2032

United States locations

U.S. sites
21
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35205 Recruiting
UCLA Hematology/Oncology - Santa Monica Los Angeles California 90404 Recruiting
Local Institution - 0050 Orange California 92868 Not yet recruiting
Local Institution - 0223 Washington D.C. District of Columbia 20007 Not yet recruiting
Baptist MD Anderson Cancer Center Jacksonville Florida 32207 Recruiting
University of Miami Hospital and Clinics, Sylvester Cancer Center Miami Florida 33136 Recruiting
Local Institution - 0228 Orlando Florida 32803 Not yet recruiting
Winship Cancer Institute, Emory University Atlanta Georgia 30322 Recruiting
Louisiana State University Health Sciences Shreveport Shreveport Louisiana 71103 Recruiting
Boston Medical Center Boston Massachusetts 02118 Recruiting
Local Institution - 0219 Minneapolis Minnesota 55455 Not yet recruiting
Local Institution - 0229 New York New York 10065 Not yet recruiting
Local Institution - 0221 Stony Brook New York 11794 Not yet recruiting
Levine Cancer Institute Charlotte North Carolina 28204 Recruiting
Cleveland Clinic Cleveland Ohio 44195 Recruiting
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 Recruiting
Local Institution - 0232 Pittsburgh Pennsylvania 15224 Not yet recruiting
Local Institution - 0227 Charleston South Carolina 29425 Not yet recruiting
Local Institution - 0184 Houston Texas 77030 Not yet recruiting
Huntsman Cancer Institute Salt Lake City Utah 84112 Recruiting
Medical College of Wisconsin Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 116 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06615479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 13, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06615479 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →